Research Summary

Jeroen is a methodologist working at the intersection of evidence synthesis, biostatistics, and health economics.

His current research interests are the clinical and economic value of precision medicine, statistical methods for network meta-analysis, and improving the transparency of health economic simulation models. Jeroen has performed applied and methods research in his areas of expertise. Notable contributions are the development of synthesis methods to overcome the typical challenges in cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. He is a co-author of a textbook on network meta-analysis for decision-making.

Education

Faculty of Human Movement Sciences, Vrije Universiteit, Netherlands, MSc, 1998, Human Movement Sciences
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, MSc, 2001, Epidemiology
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, PhD, 2004, Epidemiology

Selected Publications

  1. Jones KM, Cook-Deegan R, Rotimi CN, Callier SL, Bentley AR, Stevens H, Phillips KA, Jansen JP, Weyant CF, Roberts DE, Zielinski D, Erlich Y, Garrison NA, Carroll SR, Ossorio PN, Moreau Y, Wang M Complicated legacies: The human genome at 20.  View on PubMed
  2. Popoff E, Besada M, Jansen JP, Cope S, Kanters S Aligning text mining and machine learning algorithms with best practices for study selection in systematic literature reviews.  View on PubMed
  3. Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.  View on PubMed
  4. Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, Moore-Schiltz L, Stolshek BS The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.  View on PubMed
  5. Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".  View on PubMed
  6. Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH, Rojubally A, Jansen J, Druyts E KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.  View on PubMed
  7. Thom HZ, Jansen JP, Shafrin J, Zhao LM, Joseph G, Cheng HY, Gupta S, Shah N. Crizanlizumab and comparators for adults with sickle-cell disease: a systematic review and network meta-analysis  View on PubMed
  8. Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.  View on PubMed
  9. Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis  View on PubMed
  10. Jansen JP Heterogeneity and subgroup analysis in network meta-analysis  View on PubMed
  11. Cope S, Chan K, Jansen JP Multivariate network meta-analysis of survival function parameters.  View on PubMed
  12. Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.  View on PubMed
  13. Sussell J, Silverstein AR, Goutam P, Incerti D, Kee R, Chen CX, Batty DS, Jansen JP, Kasiske BL The economic burden of kidney graft failure in the United States.  View on PubMed
  14. Jansen JP, Incerti D, Linthicum MT Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project.  View on PubMed
  15. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-  View on PubMed
  16. Cope S, Ayers D, Zhang J, Batt K, Jansen JP Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.  View on PubMed
  17. Cope S, Keeping ST, Goldgrub R, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez-Garcia A, Yuan Y Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.  View on PubMed
  18. Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.  View on PubMed
  19. Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.  View on PubMed
  20. Garrison LP, Jansen JP, Devlin NJ, Griffin S Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework.  View on PubMed

Go to UCSF Profiles, powered by CTSI